Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 16/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 12/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876241 | 0.88 | KCNQ2 (0.40) | KCNQ2KCNQ3KCNQ4KCNQ5CNR1 | |
| SCHEMBL877424 | 0.81 | KCNQ2 (0.38) | KCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL883668 | 0.73 | KCNQ2 (0.38) | KCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL883672 | 0.72 | KCNQ2 (0.40) | KCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL12529299 | 0.66 | KCNH2 (0.41) | — | |
| SCHEMBL12529326 | 0.64 | ALDH1A1 (0.36) | SMN1; SMN2HSD17B10 | |
| SCHEMBL14108270 | 0.58 | SMN1; SMN2 (0.59) | KCNQ2KCNQ3SMN1; SMN2HSD17B10 | |
| SCHEMBL321477 | 0.57 | KCNQ3 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5HSD17B10 | |
| SCHEMBL3095470 | 0.56 | KCNQ2 (0.72) | KCNQ2KCNQ3KCNQ4KCNQ5 | |
| SCHEMBL31032186 | 0.54 | RECQL (0.37) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619202-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | Pfizer Inc (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | PFIZER INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2012038850-A1 | PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES | PFIZER INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184294-A1 | Pyrimidones for Treatment of Potassium Channel Related Diseases | KCNQ5, KCNQ1, KCNQ3 | KCNQ2 4/4885KCNQ3 3/4885KCNQ4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.